[Pharmacology of 1,4-bis(3-(3,4,5-trimethoxybenzoyloxy)-propyl)-perhydro-1,4-diazepine (dilazep I.N.N.), a new coronary active substance].
D000284:Administration, Oral; D000818:Animals; D001381:Azepines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D001565:Benzoates / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D002415:Cats; D003326:Coronary Circulation / Q000187:drug effects; D003331:Coronary Vessels / Q000187:drug effects*; D004285:Dogs; D005260:Female; D006168:Guinea Pigs; D006321:Heart / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D007267:Injections; D008297:Male; D010101:Oxygen Consumption / Q000187:drug effects; D013806:Theophylline / Q000494:pharmacology; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*
D001381:Azepines; D001565:Benzoates; D014665:Vasodilator Agents; D013806:Theophylline
Zur Pharmakologie von 1,4-Bis-(3-(3,4,5-trimethoxybenzoyl-oxy)-propyl)-perhydro-1,4-diazepin (Dilazep I.N.N.), einer neuen koronaraktiven Substanz.